相关实验视频

Updated: Jun 20, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

刺激性肠综合征患者的饮食干预反应的预测因素

Facundo Pereyra¹, Francisco Schlottmann², Carolina Salvatori¹

¹Gastroenterology Department, Cipoletti Hospital, Río Negro, Argentina.

Gastroenterologia y hepatologia

|July 19, 2024

概括

预测刺激性肠综合征 (IBS) 的改善是可能的. 在IBS患者中,高基线症状严重程度,慢性头痛和疲劳预测了低FODMAP,低粉和低糖饮食对更好的反应.

科学领域:

胃肠病学胃肠病学
饮食科学饮食科学
临床研究临床研究

背景情况:

饮食干预措施正在探索管理易怒肠综合征 (IBS).
确定IBS治疗成功的预测因素对于个性化医学至关重要.

研究的目的:

在接受特定饮食干预的IBS患者中确定症状改善的预测因素.
在IBS中开发治疗反应的预测得分.

主要方法:

一项涉及3583名IBS患者 (罗马IV标准) 的横截面研究,使用基于社交媒体的程序.
患者完成了干预前后调查,评估症状 (IBS-SSS,PHQ-9) 和肠外表现.
使用后勤回归和ROC曲线分析来识别预测因素并测试预测得分.

主要成果:

32.8%的患者表现出临床改善 (IBS-SSS下降≥50%).
高基线IBS-SSS (>400),慢性头痛和慢性疲劳与症状反应有关.
关节痛和纤维肌痛与改善的可能性较低有关.

结论:

临床变量,包括症状严重程度和特定的肠外症状,可以预测IBS的低FODMAP,低糖,低粉饮食的反应.
需要进一步的研究来阐明肠外症状与IBS饮食干预结果之间的关系.

关键词:

饮食饮食饮食饮食饮食饮食饮食饮食这是一个干预.干预干预干预刺激性肠综合征是什么意思刺激性肠道综合征刺激性肠道综合征

更多相关视频

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

相关概念视频

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...

Irritable Bowel Syndrome III: Medical and Nursing Management

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...